31 décembre 2012

Extensiv incorporation of BCHE

BCHE variants (BCHE and CHE2 Loci) associated with erythrocyte acetylcholinesterase inhibition in farmers exposed to pesticides. The findings do not support the premise that inhibitor therapy should target BuChE so as to prevent increased levels of BuChE from hydrolyzing acetylcholine in AD cerebral cortex. Thus, low BuChE in a patient's CSF may predict extensive incorporation in neuritic plaques, increased neurotoxicity and greater central neurodegeneration.
Posté par tnfalpha à 03:22 - Commentaires [0] - Permalien [#]

31 décembre 2012

Anatomical context of BCHE

Transient expression of BCHE-reporter gene constructs showed that a 194-bp fragment of the 5'-flanking region of human BCHE and a 570-bp fragment of rabbit BCHE were sufficient for promoting chloramphenicol acetyltransferase activity in HeLa cells. The objectives of our study were to examine whether the BCHE K variant is associated with Type 2 diabetes or estimates of pancreatic beta cell function in large-scale populations of glucose-tolerant Caucasians.
Posté par tnfalpha à 03:22 - Commentaires [0] - Permalien [#]
31 décembre 2012

BCHE and BuchE

An atypical form of butyrylcholinesterase or the absence of its activity leads to prolonged apnea following administration of the muscle relaxant suxamethonium. BCHE and obesity in individuals with the CHE2 C5+ and CHE2 C5- phenotypes. In this retrospective analysis, Alzheimer's disease patients younger than 75 with wild-type BuChE exhibited differential efficacy to rivastigmine, while BuChE K-variant carriers experienced similar long-term treatment effects with both agents.
Posté par tnfalpha à 03:22 - Commentaires [0] - Permalien [#]
30 décembre 2012

Activity of BCHE

Protein concentration and acetylcholinesterase (AChE) and butyrylcholinesterase (BCHE) activities were assayed in the cerebrospinal fluid (CSF) of 26 healthy normal subjects (20-86 years old), 27 patients with dementia of the Alzheimer type (DAT), and 10 patients with dementia of the Alzheimer type with extrapyramidal signs (EDAT). Scores of some of the neuropsychological tests associated with memory and attention were correlated with both plasma and CSF AChE and BuChE inhibition for up to 6 months. Pretreatment with wild-type BChE or... [Lire la suite]
Posté par tnfalpha à 02:32 - Commentaires [0] - Permalien [#]
30 décembre 2012

Psychiatry related information on BCHE

In Alzheimer's disease, BCHE may have thus acquired an inverse role to that of AChE by adopting imperfect amphipathic characteristics of its C terminus. Our results point to a possible association between an abnormal lipid metabolism and the BChE activity and might have implications as regards the pathomechanism of both Alzheimer's and vascular dementias and the cholinesterase inhibitor therapy of dementing disorders.
Posté par tnfalpha à 02:32 - Commentaires [0] - Permalien [#]
30 décembre 2012

Restriction analysis of BCHE

PvuII restriction analysis and DNA blot hybridization of the amplified ACHE and BCHE sequences demonstrated apparent aberrations in both genes, suggesting that malfunctioning of modified, partially amplified cholinesterase genes may be involved in the etiology of thrombocytopenia associated with SLE. At the clinical level, abnormal expression of both ACHE and BCHE and the in vivo amplification of the ACHE and BCHE genes has been variously associated with abnormal megakaryocytopoiesis, leukemias and brain and ovarian tumors.
Posté par tnfalpha à 02:32 - Commentaires [0] - Permalien [#]

29 décembre 2012

Entrez Gene summary for BAX

The protein encoded by this gene belongs to the BCL2 protein family. BCL2 family members form hetero- or homodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. BAX forms a heterodimer with BCL2, and functions as an apoptotic activator. This protein is reported to interact with, and increase the opening of, the mitochondrial voltage-dependent anion channel (VDAC), which leads to the loss in membrane potential and the release of cytochrome c. The expression of this gene is... [Lire la suite]
Posté par tnfalpha à 01:30 - Commentaires [0] - Permalien [#]
29 décembre 2012

BAX in immunoblotting

Significantly highernumbers of BAX positive hepatocytes were observed in HBsAg positive patients when compared to control groups. Immunoblotting revealed that BAX transfectants expressed a mean of 10-fold increased levels of BAX compared with neo-transfected control clones, with similar levels of BCL-2 and BCL-xL.
Posté par tnfalpha à 01:29 - Commentaires [0] - Permalien [#]
29 décembre 2012

Analytical, diagnostic and therapeutic context of BAX

In 47 patients with thyroid tumours (14 follicular and 3 papillary carcinomas, 14 adenomas and 16 goitres), the DNA was screened for mutations of BAX (exon 1-6) and p53 (exon 5-8) by single-strand conformation polymorphism polymerase chain reaction (SSCP-PCR). The levels of p53, BAX, BCLl-2 and p21 mRNA expression were assessed by real time RT-QPCR and the presence of respective proteins in the vessel wall was confirmed by immunohistochemistry.
Posté par tnfalpha à 01:29 - Commentaires [0] - Permalien [#]
28 décembre 2012

Cytotoxicity of BAX

The cytotoxicity of paclitaxel, vincristine, and doxorubicin was significantly enhanced in BAX transfectants compared with control clones, whereas the cytotoxicity profile of carboplatin, etoposide, and hydroxyurea was unchanged. The inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (zVAD-fmk) successfully blocked this protease activity and prevented FAS-induced death but not BAX-induced death.
Posté par tnfalpha à 03:06 - Commentaires [0] - Permalien [#]